Information Provided By:
Fly News Breaks for July 18, 2016
AGN, TEVA
Jul 18, 2016 | 06:37 EDT
HSBC analyst Steve McGarry upgraded Teva Pharmaceuticals (TEVA) to Buy saying the "imminent" closing of the Allergan (AGN) generic deal removes uncertainty and could be a catalyst for the shares. The continued pressure for Copaxone becomes less relevant post the deal, McGarry tells investors in a research note. He upped his price target for the shares to $65 from $61. Teva closed Friday down 77c to $54.21.
News For TEVA;AGN From the Last 2 Days
There are no results for your query TEVA;AGN